FDA declines to approve Allergan's Esmya Medical Dialogues Bureau24 Aug 2018 9:45 AM ISTAllergan Plc said U.S. health regulators had declined to approve Esmya, its treatment for abnormal uterine bleeding in women with uterine fibroids,...
Sage shares surge as depression drug succeeds in mid-stage trial Ruby Khatun Khatun9 Dec 2017 9:30 AM ISTDrug developer Sage Therapeutics Inc's shares soared as much as 85 percent to a record high on Thursday after its experimental drug to reduce the...
Teva's new CEO shakes up management, to combine divisions Ruby Khatun Khatun30 Nov 2017 9:15 AM ISTTEL AVIV: Teva Pharmaceutical Industries Ltd's new chief executive officer ousted the company's three top division heads on Monday as he works to turn...
US senators press Allergan for details on patent deal with tribe Ruby Khatun Khatun9 Nov 2017 9:15 AM ISTA group of U.S. senators on Tuesday asked drugmaker Allergan Plc to produce documents relating to its agreement to transfer patents to a Native...
US House committee launches probe of Allergan patent deal Ruby Khatun Khatun6 Oct 2017 9:00 AM ISTNEW YORK: A U.S. House of Representatives committee launched a probe into drugmaker Allergan Plc's deal to transfer some of its patents to a Native...
US tribal patent deal could have big impact on generic drug market Ruby Khatun Khatun14 Sept 2017 9:45 AM ISTA groundbreaking deal between Allergan Plc and a Native American tribe to shield the company's patents in administrative proceedings could also be...
Drugmaker Teva hires Lundbeck CEO Schultz to restore its health Ruby Khatun Khatun12 Sept 2017 9:47 AM ISTJERUSALEM/COPENHAGEN: Teva poached Lundbeck's Kare Schultz as its new chief executive on Monday, handing the drugs industry veteran the urgent task of...
Exclusive: Pfizer weighs sale or spin off of consumer health unit - sources supriya kashyap kashyap10 Nov 2016 1:32 PM ISTn" style="transform: translate3d(0px, 0px, 0px);"U.S. drugmaker Pfizer Inc is evaluating a potential sale or spin-off of its consumer health division...
